Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Director | June 17, 2026 | June 18, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director · President and CEO | November 27, 2018 | November 30, 2018 |
| Kailera Therapeutics, Inc.KLRA · Entity 4435 | Director | April 16, 2026 | April 20, 2026 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | Director | June 03, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.42 · Expires 2036-06-16 | Direct | 75,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 75,000 · Balance 75,000 F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).
GILEAD SCIENCES, INC.
Report date November 27, 2018 · Filed November 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,574,306 |
Reported balance
After 2018-11-27 transaction · row 1
1 source rowRow 1 · 2018-11-27 · Exercise / conversion · Acquired 280,000 · Balance 1,574,306 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.60 · Expires 2019-01-21 | Direct | 0 |
Reported balance
After 2018-11-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-11-27 · Exercise / conversion · Disposed 280,000 · Balance 0 F1: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
Kailera Therapeutics, Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 38,300 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 38,300 · Balance 38,300 F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2036-06-03 | Direct | 223,492 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 223,492 · Balance 223,492 F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2007 Filed Feb 26, 2007 20:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,816 | $0.00 Strike: $7.40 | $0.00 |
DisclosureSEC source: 0001179110-07-004696 · edgar.xml · derivative · entry 11 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,816 shares Expires 2011-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vested 20% on January 18, 2002, the first anniversary of the grant. The balance will vested 5% every three months thereafter and was fully vested as of January 18, 2006. Read SEC document |
| February 22, 2007 Filed Feb 26, 2007 20:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 700 | $73.67 | $51,569.00 |
DisclosureSEC source: 0001179110-07-004696 · edgar.xml · nonDerivative · entry 10 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,301 Read SEC document |
| February 22, 2007 Filed Feb 26, 2007 20:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $73.66 | $7,366.00 |
DisclosureSEC source: 0001179110-07-004696 · edgar.xml · nonDerivative · entry 9 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,001 Read SEC document |
| February 22, 2007 Filed Feb 26, 2007 20:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,000 | $73.65 | $294,600.00 |
DisclosureSEC source: 0001179110-07-004696 · edgar.xml · nonDerivative · entry 8 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,101 Read SEC document |
| February 22, 2007 Filed Feb 26, 2007 20:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,400 | $73.64 | $103,096.00 |
DisclosureSEC source: 0001179110-07-004696 · edgar.xml · nonDerivative · entry 7 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,101 Read SEC document |
| February 22, 2007 Filed Feb 26, 2007 20:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,100 | $73.63 | $80,993.00 |
DisclosureSEC source: 0001179110-07-004696 · edgar.xml · nonDerivative · entry 6 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,501 Read SEC document |
| February 22, 2007 Filed Feb 26, 2007 20:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 400 | $73.61 | $29,444.00 |
DisclosureSEC source: 0001179110-07-004696 · edgar.xml · nonDerivative · entry 5 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,601 Read SEC document |
| February 22, 2007 Filed Feb 26, 2007 20:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,600 | $73.60 | $191,360.00 |
DisclosureSEC source: 0001179110-07-004696 · edgar.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,001 Read SEC document |
| February 22, 2007 Filed Feb 26, 2007 20:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 9,700 | $73.59 | $713,823.00 |
DisclosureSEC source: 0001179110-07-004696 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,601 Read SEC document |
| February 22, 2007 Filed Feb 26, 2007 20:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 16,184 | $9.81 | $158,765.04 |
DisclosureSEC source: 0001179110-07-004696 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2007 Filed Feb 26, 2007 20:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,816 | $7.40 | $28,232.68 |
DisclosureSEC source: 0001179110-07-004696 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2007 Filed Jan 24, 2007 21:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $65.58 | $0.00 |
DisclosureSEC source: 0001179110-07-001867 · edgar.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2017-01-22 F1 · derivative.exercise_date: Options vest over a five year period beginning 1/22/2008, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 1/22/2012. Read SEC document |
| December 20, 2006 Filed Dec 22, 2006 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 4,060 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001179110-06-024182 · edgar.xml · derivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,060 shares Expires 2010-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vested 20% on January 26, 2001, the first anniversary date of the grant. The remaining balance vested quarterly over a four year period and was fully vested on January 26, 2005. Read SEC document |
| December 20, 2006 Filed Dec 22, 2006 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 4,060 | $7.08 | $28,737.49 |
DisclosureSEC source: 0001179110-06-024182 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.40 | $0.00 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · derivative · entry 21 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,816 Underlying: Common Stock · 30,000 shares Expires 2011-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested 20% on January 18, 2002, the first anniversary date of the grant. The balance vested every three months thereafter until fully vested on January 18, 2006 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 8,312 | $68.61 | $570,286.32 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 20 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,241 F2 · balance_after: Amount of Securities Beneficially Owned Following Reported Transaction (s) (Table 1, Col. 5) includes 720 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on June 30, 2006 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $68.62 | $13,724.00 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 19 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,553 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $68.63 | $13,726.00 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 18 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,753 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 800 | $68.64 | $54,912.00 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 17 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,953 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,730 | $68.65 | $393,364.50 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 16 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,753 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $68.67 | $6,867.00 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 15 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,483 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 400 | $68.66 | $27,464.00 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 14 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,583 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,516 | $68.68 | $104,118.88 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 13 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,983 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,200 | $68.69 | $82,428.00 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 12 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,499 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $68.70 | $34,350.00 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 11 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,699 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $68.71 | $13,742.00 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 10 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,199 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,400 | $68.72 | $233,648.00 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 9 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,399 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 300 | $68.73 | $20,619.00 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 8 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,799 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,700 | $68.75 | $323,125.00 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 7 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,099 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,000 | $68.76 | $68,760.00 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 6 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,799 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $68.79 | $13,758.00 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 5 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,799 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $68.82 | $6,882.00 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,999 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,042 | $68.89 | $71,783.38 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,099 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $68.84 | $6,884.00 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,141 Read SEC document |
| October 30, 2006 Filed Oct 31, 2006 23:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 30,000 | $7.40 | $221,955.00 |
DisclosureSEC source: 0001179110-06-020616 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2006 Filed Jul 26, 2006 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 17,824 | $0.00 Strike: $11.76 | $0.00 |
DisclosureSEC source: 0001179110-06-015611 · edgar.xml · derivative · entry 14 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,824 shares Expires 2010-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested 20% on November 8, 2001, the first anniversary date of the grant. The balance vested every three months thereafter until fully vested on November 8, 2005. Read SEC document |
| July 25, 2006 Filed Jul 26, 2006 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 42,176 | $0.00 Strike: $7.40 | $0.00 |
DisclosureSEC source: 0001179110-06-015611 · edgar.xml · derivative · entry 13 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,816 Underlying: Common Stock · 42,176 shares Expires 2011-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested 20% on January 18, 2002, the first anniversary date of the grant. The balance vested every three months thereafter until fully vested on January 18, 2006 Read SEC document |
| July 25, 2006 Filed Jul 26, 2006 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $60.94 | $30,470.00 |
DisclosureSEC source: 0001179110-06-015611 · edgar.xml · nonDerivative · entry 12 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,521 Read SEC document |
| July 25, 2006 Filed Jul 26, 2006 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,345 | $60.87 | $264,480.15 |
DisclosureSEC source: 0001179110-06-015611 · edgar.xml · nonDerivative · entry 11 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,021 Read SEC document |
| July 25, 2006 Filed Jul 26, 2006 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,149 | $60.85 | $191,616.65 |
DisclosureSEC source: 0001179110-06-015611 · edgar.xml · nonDerivative · entry 10 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,366 Read SEC document |
| July 25, 2006 Filed Jul 26, 2006 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 900 | $60.84 | $54,756.00 |
DisclosureSEC source: 0001179110-06-015611 · edgar.xml · nonDerivative · entry 9 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,515 Read SEC document |
| July 25, 2006 Filed Jul 26, 2006 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,000 | $60.83 | $60,830.00 |
DisclosureSEC source: 0001179110-06-015611 · edgar.xml · nonDerivative · entry 8 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,415 Read SEC document |
| July 25, 2006 Filed Jul 26, 2006 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 300 | $60.82 | $18,246.00 |
DisclosureSEC source: 0001179110-06-015611 · edgar.xml · nonDerivative · entry 7 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,415 Read SEC document |
| July 25, 2006 Filed Jul 26, 2006 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,684 | $60.81 | $345,644.04 |
DisclosureSEC source: 0001179110-06-015611 · edgar.xml · nonDerivative · entry 6 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,715 Read SEC document |
| July 25, 2006 Filed Jul 26, 2006 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,546 | $60.80 | $93,996.80 |
DisclosureSEC source: 0001179110-06-015611 · edgar.xml · nonDerivative · entry 5 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,399 Read SEC document |
| July 25, 2006 Filed Jul 26, 2006 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 400 | $60.79 | $24,316.00 |
DisclosureSEC source: 0001179110-06-015611 · edgar.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,945 Read SEC document |
| July 25, 2006 Filed Jul 26, 2006 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 17,824 | $11.76 | $209,572.81 |
DisclosureSEC source: 0001179110-06-015611 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2006 Filed Jul 26, 2006 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 42,176 | $60.80 | $2,564,300.80 |
DisclosureSEC source: 0001179110-06-015611 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,521 Read SEC document |
| July 25, 2006 Filed Jul 26, 2006 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 42,176 | $7.40 | $312,039.14 |
DisclosureSEC source: 0001179110-06-015611 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2006 Filed Feb 7, 2006 21:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $11.76 | $0.00 |
DisclosureSEC source: 0001179110-06-003018 · edgar.xml · derivative · entry 14 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,824 Underlying: Common Stock · 30,000 shares Expires 2010-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested 20% on November 8, 2001, the first anniversary date of the grant. The balance vested every three months thereafter until fully vested on November 8, 2005. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.